NO20063155L - Anti-IGF-I receptor antibody - Google Patents

Anti-IGF-I receptor antibody

Info

Publication number
NO20063155L
NO20063155L NO20063155A NO20063155A NO20063155L NO 20063155 L NO20063155 L NO 20063155L NO 20063155 A NO20063155 A NO 20063155A NO 20063155 A NO20063155 A NO 20063155A NO 20063155 L NO20063155 L NO 20063155L
Authority
NO
Norway
Prior art keywords
igf
antibodies
receptor
cancer
elevated level
Prior art date
Application number
NO20063155A
Other languages
Norwegian (no)
Inventor
Rajeeva Singh
Daniel J Tavares
Nancy E Dagdigian
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of NO20063155L publication Critical patent/NO20063155L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Antistoffer, humaniserte antistoffer, overflatemodifiserte antistoffer,antistoffragmenter, derivatiserte antistoffer og konjugater av disse med cytotoksiske midler, som spesifikt bindes til og inhiberer insulinlignende vekstfaktor-1-reseptor, antagoniserer virkningene av IGF-I, IGF-II og serum på vekst og overlevelse av tumorceller og som i det vesentlige er frie for agonistaktivitet. Antistoffene og fragmentene av disse kan, om ønskelig sammen med andre terapeutiske midler, anvendes ved behandling av tumorer som uttrykker forhøyet nivå av IGF-I-reseptor, feks. brystkreft, kolonkreft, lungekreft, ovariekarsinom, synovialkarsinom, prostatakreft og bukspyttkjertelkreft, og de derivatiserte antistoffene kan anvendes ved diagnose og synliggjøring av tumorer som uttrykker forhøyet nivå av IGF-I-reseptor.Antibodies, humanized antibodies, surface-modified antibodies, antibody fragments, derivatized antibodies and their conjugates with cytotoxic agents that specifically bind to and inhibit insulin-like growth factor-1 receptor antagonize the effects of IGF-I, IGF-II, and serum on growth. tumor cells and which are essentially free of agonist activity. The antibodies and fragments thereof, if desired together with other therapeutic agents, may be used in the treatment of tumors expressing elevated level of IGF-I receptor, e.g. breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial carcinoma, prostate cancer and pancreatic cancer, and the derivatized antibodies can be used in the diagnosis and visualization of tumors expressing elevated level of IGF-I receptor.

NO20063155A 2003-12-08 2006-07-07 Anti-IGF-I receptor antibody NO20063155L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody
PCT/US2004/038230 WO2005061541A1 (en) 2002-06-14 2004-12-07 Anti-igf-i receptor antibody

Publications (1)

Publication Number Publication Date
NO20063155L true NO20063155L (en) 2006-08-11

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063155A NO20063155L (en) 2003-12-08 2006-07-07 Anti-IGF-I receptor antibody

Country Status (13)

Country Link
EP (1) EP1692176A4 (en)
JP (1) JP2008502589A (en)
KR (1) KR20070001883A (en)
CN (1) CN1886424A (en)
AU (1) AU2004303792A1 (en)
BR (1) BRPI0417406A (en)
CA (1) CA2548065A1 (en)
CR (1) CR8426A (en)
EA (1) EA009807B1 (en)
EC (1) ECSP066595A (en)
IL (1) IL174770A0 (en)
MX (1) MXPA06005540A (en)
NO (1) NO20063155L (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101989628B1 (en) 2009-12-21 2019-06-14 제넨테크, 인크. Antibody formulation
MX2012013068A (en) * 2010-05-11 2013-03-05 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies.
WO2013055699A1 (en) * 2011-10-10 2013-04-18 Children's Hospital Los Angeles Novel asparaginase and methods for treating diseases associated with asparagine dependence
CN103509117B (en) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 Bi-specific antibody of anti-human HER2 and people IGF-IR and its production and use
KR20220051270A (en) * 2017-05-30 2022-04-26 데이진 화-마 가부시키가이샤 Anti-igf-i receptor antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351452A1 (en) * 1998-12-04 2000-06-15 Novartis Ag Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3
AR032028A1 (en) * 2001-01-05 2003-10-22 Pfizer ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
NZ540971A (en) * 2003-02-13 2008-04-30 Pfizer Prod Inc Uses of anti-insulin-like growth factor I receptor antibodies

Also Published As

Publication number Publication date
CN1886424A (en) 2006-12-27
AU2004303792A1 (en) 2005-07-07
IL174770A0 (en) 2006-08-20
CR8426A (en) 2007-12-04
EP1692176A1 (en) 2006-08-23
JP2008502589A (en) 2008-01-31
EP1692176A4 (en) 2008-11-12
BRPI0417406A (en) 2007-04-03
EA200600931A1 (en) 2006-10-27
MXPA06005540A (en) 2006-08-17
EA009807B1 (en) 2008-04-28
CA2548065A1 (en) 2005-07-07
ECSP066595A (en) 2006-10-17
KR20070001883A (en) 2007-01-04

Similar Documents

Publication Publication Date Title
SG141243A1 (en) Anti-igf-i receptor antibody
Subbiah et al. Multimodality treatment of desmoplastic small round cell tumor: chemotherapy and complete cytoreductive surgery improve patient survival
Ristau et al. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research
Fong et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer
Wernicke et al. Prostate‐specific membrane antigen expression in tumor‐associated vasculature of breast cancers
EP1996716A4 (en) Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
EA200970130A1 (en) ANTAGONISTIC ANTIBODE FOR CANCER TREATMENT
Errarte et al. The expression of fibroblast activation protein in clear cell renal cell carcinomas is associated with synchronous lymph node metastases
WO2006099141A3 (en) Anti-mesothelin antibodies
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
MX2021015888A (en) Fusion of an antibody binding cea and 4-1bbl.
MX2009012838A (en) Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label.
WO2009032949A3 (en) High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2007149948A3 (en) Compositions and methods for diagnosis and treatment of tumors
NO20063155L (en) Anti-IGF-I receptor antibody
EA200601405A1 (en) HUMANIZED ANTIBODY
WO2005094348A3 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
Dimitrakopoulos et al. NSCLC and the alternative pathway of NF-κB: uncovering an unknown relation
EP1539818A4 (en) Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
Pawlikowski et al. Overexpression of prothymosin alpha is related to pituitary adenoma recurrence but not to adenoma invasiveness and proliferation
ATE288960T1 (en) HUMANIZED MONOCLONAL ANTIBODIES WITH HIGH AFFINITY AGAINST DAY-72
NO20004251L (en) Humanized anti-CEA high affinity monoclonal antibodies
Yildirim et al. Concurrent epithelioid malignant peripheral nerve sheath tumor and papillary thyroid carcinoma in the treated field of Hodgkin's disease
WO2006078892A3 (en) Use of a novel prostate specific membrane antigen for cancer diagnosis and therapy
Horstmann et al. 384: BFGF Expression in the Invasion Front of the Tumor Reflects the Aggressiveness of Renal Cell Cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application